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ABSTRACT
Most cancers are sporadic, but 5-10% of all cancer is hereditary, or caused by a
heritable genetic mutation. A patient’s medical history, family history, genetic test
results, intact organs (e.g., ovaries) at an increased risk for developing cancer, and the
availability and accessibility of interventions are used to make recommendations for
cancer-risk management. In addition to basic medical care, transgender patients have
healthcare needs that differ from those of cisgender patients such as expert care related to
using hormones or having gender-affirming surgery, as well as unique mental health
concerns. Transgender individuals may also experience a greater number of barriers to
accessing care than cisgender individuals.
The purpose of this study was to explore the motivations and needs of transgender
individuals who may seek cancer genetic counseling. We aimed to determine where
current practices could be improved to increase comfortability and inclusivity of
transgender patients. Eighty-seven transgender individuals participated in an online
questionnaire that asked about their personal perspectives on comfort and preferences
regarding current genetic counseling practices.
Most participants reported that they would feel comfortable sharing their pronouns,
hormone therapies, and surgical history on an intake form before their genetic counseling
appointment. The results suggested that comfort levels between the different current
practices regarding pedigree nomenclature had no statistical differences, although most
participants would not be comfortable being represented as their sex assigned at birth on
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a pedigree. When assessing motivations, evidence demonstrated that most participants
would want to discuss how hormone and surgical therapies could impact personal cancer
risk. These findings reinforce recommendations from existing literature regarding the
adaptation and evolution of current practices to meet the needs of transgender patients
while highlighting the need for standardized training in order to provide comprehensive,
inclusive care for all patients, regardless of gender identity.
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CHAPTER 1
BACKGROUND
1.1 Introduction to Hereditary Cancer
Cancer is one of the most prevalent diseases worldwide. The National Cancer
Institute (NCI) is the principal agency for conducting and supporting cancer research,
prevention, diagnosis, and treatment in the United States. The NCI has been documenting
cancer incidence data in the Surveillance, Epidemiology, and End Results (SEER)
Program since 1973 and makes the data publicly accessible online. According to SEER,
there were 1,806,590 new cases of cancer in 2020. While most cancers are sporadic,
approximately 5-10% of all cancer is hereditary – it occurs in a person with a heritable
genetic mutation in a cancer predisposition gene (Dalton et al., 2014). When an
individual has a genetic predisposition to cancer, they are at an increased risk for
developing certain types of cancer depending on which gene has a mutation. Hereditary
cancers tend to occur at younger ages than sporadic cancers and individuals with a
hereditary cancer syndrome can have multiple cancers in their lifetime.
Based on these risks, the National Comprehensive Cancer Network (NCCN) has
published guidelines for genetic testing for hereditary cancer syndromes and cancer risk
management in individuals who have hereditary cancer predisposition syndromes. These
recommendations for cancer screenings and preventative therapies aim to reduce the
probability that cancer will occur or reoccur in these individuals. For example, the NCCN
Guidelines for Genetic/Familial High-Risk Assessment for Breast, Ovarian, and

1

Pancreatic cancers include criteria for factors in an individual’s personal and family
medical history make them an appropriate candidate for genetic counseling and genetic
testing. Some of these factors include being diagnosed with breast cancer under 46-yearsold, metastatic prostate cancer at any age, or having a blood relative with a known
mutation in a cancer susceptibility gene (NCCN 2020).
If someone is found to be at an increased risk for developing cancer based on their
family history or their genetic testing results, the NCCN recommends earlier and
increased cancer surveillance. Some of these recommendations include starting breast
magnetic-resonance imaging (MRI), mammograms, colonoscopies, endoscopies, and
other screenings at younger ages or undergoing these cancer screenings more frequently
in order to identify cancers earlier and optimize any necessary treatment.
1.2 Genetic Counseling and Testing for Cancer Predispositions
Physicians use the NCCN guidelines as well as other recommendations from
professional societies such as the American Cancer Society, American College of
Obstetricians and Gynecologists, and the American College of Medical Genetics and
Genomics to determine which of their patients need to be referred to a genetic counselor,
based on that individual’s personal and family history.
Genetic counselors are healthcare professionals with training in both medical genetics
and psychosocial counseling. A cancer genetic counselor specializes in evaluating
patients for hereditary cancer syndromes. In a typical cancer genetic counseling session,
the genetic counselor elicits a patient’s personal and family medical history and conducts
a risk assessment to determine the likelihood that a patient’s cancer or the cancer in their
family may be caused by a genetic predisposition syndrome. The genetic counselor then
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communicates that risk assessment to the patient, facilitates decision making regarding
options for genetic testing, educates the patient on cancer surveillance and prevention,
and arranges genetic testing when appropriate (Schneider, 2011). During a genetic
counseling session, the counselor also explores psychosocial issues regarding motivations
for testing, feelings about the risk information, and overall emotional state of the patient.
When eliciting a patient’s family history, the genetic counselor will document the
information as a pedigree, or a diagram of the family tree. Once the pedigree is drawn,
the genetic counselor looks for patterns that are consistent with those seen in hereditary
cancer syndromes and presents this information to the patient as a probability that they
could have a hereditary cancer syndrome. The goal of providing this information is to aid
in the patient’s decision making about genetic testing and future medical management. If
a patient decides to pursue genetic testing, the genetic counselor helps them with
decisions regarding appropriate testing and follow-up (Glessner et al., 2012).
The National Society of Genetic Counselors (NSGC) has established Practice
Guidelines for Human Pedigree Nomenclature. The purpose of these guidelines is to
create a standardized way to accurately and appropriately represent individuals, their
relationships, and their medical status for risk assessment and future reference for other
medical providers (Bennett et al., 2008). Traditionally, based on the binarization of
gender in most Western cultures, females and males have been represented by circles and
squares, respectively. If an individual’s gender is unknown, they may be represented by a
diamond (Bennett et al., 2008; Sutherland et al., 2020).
The most recent update to these guidelines was in 2008, which recommended a
standardized way of representing transgender individuals. However, periodic revision of
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these guidelines is imperative to ensure inclusivity of all patients (Sheehan et al., 2020).
The NCCN and NSGC guidelines on how to represent transgender individuals on a
pedigree differ and there is currently no universally accepted and standardized way to
represent gender identity and sex assigned at birth. The lack of consensus creates
confusion between medical professionals and does not validate the gender identity of
transgender patients. There have been suggestions to create a unique symbol for
transgender and nonbinary patients within the field of genetic counseling, which
underlines the need for standardization and reform of the current practice guidelines
(Sheehan et al., 2020; Tuite et al., 2020).
1.3 Overview of Transgender Healthcare
A person’s sexuality and gender are made up of many features including gender
identity, gender expression, sex assigned at birth, and sexual orientation. Several
transgender education and advocacy organizations have published infographics to explain
these aspects of the gender and sexuality spectrums. To describe gender identity, three
independent spectrums are used to measure the degree to which someone identifies with
the female gender, male gender, or other genders (Coleman et al., 2012). Gender
expression is the degree to which someone outwardly expresses themselves in a feminine,
androgenous, or masculine way. In the United States, children are typically assigned
male, female, or intersex at birth before their gender identity is developed, which is
known as “sex assigned at birth” (Puechl et al., 2019).
According to the Centers for Disease Control and Prevention’s (CDC) 2018
Behavioral Risk Factor Surveillance System (BRFSS), over 1.4 million Americans
identify as transgender and/or nonbinary. The term “transgender” is used to describe
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people whose gender identity does not align with their sex assigned at birth. “Cisgender”
is a term used to describe individuals whose gender identity does alighn with their sex
assigned at birth. Someone who is transgender may identify with the female gender, male
gender, another gender, no gender, or a combination of genders. Someone who does not
identify with the female or male genders may describe their gender as “nonbinary”
(Rafferty, 2018). When a person’s gender does not align with their sex assigned at birth,
they may choose to express their gender through social changes, hormonal therapies,
and/or surgical transitions.
The World Professional Association for Transgender Health (WPATH) published
Standards of Care for the Health of Transsexual, Transgender, and GenderNonconforming People. These guidelines describe therapies available to aid in the
transition from sex assigned at birth to true gender, including hormonal and surgical
options. Hormone therapy is the use of hormones to induce more feminine or masculine
secondary sex characteristics. Changes that occur in individuals who are prescribed
gender-affirming hormones typically occur over the course of two to five years. There are
some possible risks to taking these hormones, including a potential increase in cancer
risk, although much of the data is minimal and sometimes conflicting (Sutherland et al.,
2020).
Gender-affirming surgeries may involve altering an individual’s breast tissue, ovaries,
and genitalia. Breast and chest reconstruction may be referred to as “top surgery” and
typically involves either a breast augmentation mammoplasty or a subcutaneous
mastectomy with chest contouring (Coleman et al., 2012). Subcutaneous, or nipplesparing mastectomies, are not typically prophylactic bilateral total mastectomies, which is
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the recommended surgical prevention for some high-risk hereditary breast cancer
syndromes (Guillem et al., 2020). Additional surgical transitions may include “bottom
surgery,” or surgery involving reproductive and/or genital organ reconstruction or
removal (Coleman et al., 2012). Surgery to remove reproductive organs such as the uterus
(hysterectomy) or ovaries and fallopian tubes (salpingo-oophorectomy) may be available
for gender-affirming surgery. Currently, a risk-reducing bilateral salpingo-oophorectomy
(BSO) is the most effective means of decreasing ovarian cancer risk in individuals with
high-risk hereditary cancer syndromes Guillem et al., 2020). This surgery is performed
differently and removes larger amount of tissue than a BSO for non-risk-reducing
reasons, such as surgical transition. Surgery to remove the prostate (prostatectomy) is not
typically offered as part of a gender-affirming surgery and is also not typically
recommended as a risk-reduction option in most cases of high-risk hereditary cancer
syndromes. Possible risks associated with gender-affirming surgeries are those of typical
surgery-related complications (Coleman et al., 2012). Because there is limited data on the
effects that these therapies have on cancer risk, transgender and gender nonconforming
patients who present for cancer risk assessment require a more personalized approach to
discussing gender-affirming interventions and management options (Sutherland et al.,
2020).
1.4 Health Disparities in Cancer Care
There are significant barriers that limit access to gender-affirming therapies and
general healthcare services among gender-diverse populations (Berro, et al., 2019; Harb
et al., 2019; Haviland et al., 2020; Sacca et al., 2019; Sutherland et al., 2020; Zayhowski
et al., 2019). These barriers include lack of competent care, inhibited access to health
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insurance, and limited availability of inclusive and comfortable healthcare environments
(Edmiston et al., 2016; Harb et al., 2019; Haviland et al., 2020). It has been shown that
healthcare providers with professional education and formal training regarding care for
lesbian, gay, bisexual, transgender, and questioning (LGBTQ) individuals demonstrate an
increase in knowledge and competency when serving these patient populations
(Hardacker et al., 2014; Johnson et al., 2016). Patients who are currently employed, have
higher annual incomes, have completed higher levels of education, and have health
insurance are more likely to adhere to cancer screening and prevention recommendations
than those who do not (Johnson et al., 2016). Adults who are of ethnic minorities are
more likely than white adults to identify as a gender minority, which can compound these
barriers and further limit and prevent access to medical care, ultimately leading to worse
health outcomes (Center for Disease Control and Prevention 2018).
Without accurate, standardized documentation of gender diversity in most medical
record systems, cancer rates among transgender people are poorly understood. The SEER
database does not collect gender identity information, therefore there is no way to
determine cancer rates among transgender patients at a population level. Individuals who
are at high risk for developing cancer, including individuals with hereditary cancer
syndromes, have specific screening recommendations that they should follow based on
the specific body tissues they have. Based on the information that is available,
transgender individuals have been reported to have extremely low uptake on all cancer
screenings. Transgender and gender-nonconforming individuals have lower proportions
of routine colorectal cancer screening compared to cisgender individuals (Tabaac et al.,
2018). Transgender individuals are also less likely to adhere to breast cancer screening
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recommendations (Bazzi et al., 2015). Receiving less cancer surveillance contributes to
increased time to cancer diagnosis which leads to increased rates of morbidity and
mortality among transgender patients (Sutherland et al., 2020).
High-risk individuals who have at-risk body tissues, regardless of gender, should
follow the NCCN Guidelines for hereditary cancer management. However, there are no
evidence-based cancer screening guidelines specifically for transgender patients. Breast
tissue, one or both ovaries, a uterus, and/or a prostate are of specific importance to
transgender individuals, because these body systems are at an increased risk for tumor
development with many genetic predisposition syndromes. Additionally, some
individuals may have elected to have that tissue removed before the genetic counseling
session or may want to learn more about their options for removal of certain at-risk
tissues during the session. Transgender men may elect to have chest surgery to create a
more masculine appearance, however, this does not eliminate their breast cancer risk, as
there is some residual tissue left over (Alaofi et al., 2018; Griepsma et al., 2014).
Some research has been published regarding care for sexual minorities, however,
gender diverse individuals are vastly underrepresented in literature regarding cancer
screening and genetic counseling (Haviland et al., 2020). The transgender population is
generally absent from the little data that does exist on LGBTQ individuals
(VandenLangenberg et al., 2011). In the studies that include lesbian, gay, and bisexual
patients, genetic counselors report overall that they do not adjust their counseling
approaches (Glessner et al., 2012). When it comes to pedigree drawing, genetic
counselors have standard nomenclature dictated by NSGC and the NCCN on how to
represent different individuals, relationships, and disease status, which, in a cancer
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setting, would be cancer diagnoses. The information that exists on how to represent
transgender and gender-nonconforming individuals is limited and inconsistent (Berro et
al., 2019; Sheehan et al., 2020). The inconsistencies in recommendations from national
organizations make it difficult to properly represent these individuals in a standardized,
informative, and respectful way.
1.5 Rationale
Little research has been conducted to assess the feelings and experiences of
transgender patients regarding current genetic counseling practices. Most of the
information that is available comes from case studies or from the perspective of genetic
counselors rather than of transgender community members. Additionally, each of these
studies calls for a greater exploration of the views of transgender patients themselves. To
our knowledge, no research has been conducted to assess the perspectives of transgender
individuals who have not had cancer genetic counseling specifically regarding anticipated
needs and perceived barriers to accessing genetics care.
The identification of a pathogenic genetic variant that increases someone’s risk to
develop cancer could impact a transgender patient’s decisions about hormonal or surgical
medical interventions. There is limited information available on the unique needs of
transgender individuals in a cancer genetic counseling session. This population may be a
significant portion of the patients seen in clinics, and there are currently no standardized
guidelines or recommendations for how to care for transgender patients in a cancer
genetics setting (Barnes et al., 2019; Rafferty 2018; Sheehan et al., 2020). To meet the
needs of this patient population, patient perspectives must be assessed. This study aimed
to determine what aspects of current genetic counseling practice and training need to be
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adapted to benefit this patient population. We anticipated that the results of the study
would aid in the optimization and standardization of cancer genetic counseling strategies
for transgender patients.
1.6 Purpose
This project was conducted to assess the anticipated needs of transgender adults
during a cancer genetic counseling session. The primary goal of this study was to
determine the informational and psychosocial needs of transgender patients who may
present for cancer genetic counseling. This study also aimed to identify motivations and
barriers to seeking genetic counseling. The information collected was be compared to
previously reported perspectives of cancer genetic counselors on their experiences with
counseling transgender individuals about hereditary cancer risk. Finally, through this
study, we hoped to recognize themes to assist in standardization of practice and
optimization of care of gender minority patients.
This study aimed to provide genetic counseling research surrounding transgender
healthcare, which is currently sparse and limited. While there is literature that assesses
the needs of patients who identify as a sexual minority, research regarding how genetic
counselors can meet the needs of transgender patients specifically is minimal. In the
NSGC 2020 Professional Status Survey–an internally administered survey that assesses
metrics of current genetic counselors such as demographics, salary, and workforce
satisfaction–only two genetic counselors indicated non-binary or third gender identities.
The literature that does exist regarding transgender patients is predominantly from the
perspective of genetic counselors, most of whom do not identify as transgender or nonbinary, leaving the transgender voice largely absent. The informational, psychosocial, and

10

medical management needs of transgender individuals is likely different from those of
cisgender patients. Therefore, it is important to explore the perspectives of these patients
to gain information about how best to care for them. Without intentional surveying of
gender minority patients, genetic counselors will remain underprepared to care for a
portion of the patient population. In existing literature, genetic counselors indicated a
desire for more data and education regarding counseling transgender patients (Zayhowski
et al., 2019).
Identifying the needs of transgender patients adds to the cultural competence that
genetic counselors must have to effectively serve patients, making the information gained
from exploring these perspectives valuable to the profession. Cultural competency is a
core value of the genetic counseling field, as it encourages genetic counselors to
understand each patient’s family, community, and culture to better empathize with
patients’ thoughts, feelings, and values. Understanding the motivations and needs of
transgender people who may present for cancer genetic counseling is the only way to
competently counsel these patients. It is the duty of genetic counselors to be
knowledgeable and sensitive to diverse languages, cultures, beliefs, and backgrounds to
provide optimal care (Warren & Wilson 2013). The information gained from surveying
patients directly will prepare current and future genetic counselors for interactions with
all patients, including transgender and gender nonconforming patients.
We predicted that transgender individuals have needs within the cancer genetic
counseling session that are similar to cisgender patients as well as needs that are unique
to their gender identity. We expected that transgender individuals would find value in
discussing how future healthcare plans regarding gender-affirming therapies could be
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impacted by a hereditary predisposition to cancer. Results from this study may also
provide clarification on current practices regarding official pedigree standards.
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CHAPTER 2
ASSESSING THE ANTICIPATED NEEDS OF TRANSGENDER PATIENTS IN
CANCER GENETIC COUNSELING1

1

Baquet, J., Koeller, D., Nunley, P., and Tomlin, K. To be submitted to Journal of
Genetic Counseling.
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2.1 Abstract
Most cancers are sporadic, but 5-10% of all cancer is hereditary, or caused by a
heritable genetic mutation. A patient’s medical history, family history, genetic test
results, intact organs (e.g., ovaries) at an increased risk for developing cancer, and the
availability and accessibility of interventions are used to make recommendations for
cancer-risk management. Transgender patients have healthcare needs that differ from
those of cisgender patients such as expert care related to using hormones or having
gender-affirming surgery, as well as unique mental health concerns. Transgender
individuals may also experience a greater number of barriers to accessing care than
cisgender individuals.
The purpose of this study was to explore the motivations and needs of transgender
individuals who may seek cancer genetic counseling. We aimed to determine where
current practices could be improved to increase comfortability and inclusivity of
transgender patients. Eighty-seven transgender individuals participated in an online
questionnaire that asked about their personal perspectives on comfort and preferences
regarding current genetic counseling practices.
Most participants reported that they would feel comfortable sharing their pronouns,
hormone therapies, and surgical history on an intake form before their genetic counseling
appointment. The results suggested that comfort levels between the different current
practices regarding pedigree nomenclature had no statistical differences, although most
participants would not be comfortable being represented as their sex assigned at birth on
a pedigree. When assessing motivations, survey responses demonstrated that most
participants would want to discuss how hormone and surgical therapies impact personal
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cancer risk. These findings reinforce recommendations from existing literature regarding
the adaptation and evolution of current practices to meet the needs of transgender patients
while highlighting the need for standardized training in order to provide comprehensive,
inclusive care for all patients, regardless of gender identity.
2.2 Introduction
A person’s sexuality and gender are made up of many features including gender
identity, gender expression, sex assigned at birth, and sexual orientation (see Table 2.1
for a glossary of terms used in this paper). In the United States, where children are
typically assigned a sex at birth before they develop their gender identity, over one
million Americans identify as transgender and/or nonbinary (Puechl et al., 2019, Rafferty
2018). When a person’s gender does not align with their sex assigned at birth, they may
choose to express their gender through social changes, hormonal therapies, and/or
surgical transitions.

Table 2.1 Glossary of Terms
Term

Definition

Cis/Cisgender

Used to describe a person whose gender identity and gender
expression align with sex assigned at birth and culturally
defined gender roles.

Gender

Refers to the attitudes, feelings, and behaviors that a given
culture associates with a person’s assigned sex.

Gender Dysphoria

Discomfort of distress related to incongruence between a
person's gender identity, sex assigned at birth, and/or primary
sex characteristics.

Gender Expression

The presentation of an individual, including physical
appearance, clothing choice and accessories, and behaviors
that express aspects of gender identity or role.

Gender Identity

A person's inherent sense of self as it relates to gender.
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Nonbinary

Used to describe a person whose gender identity does not
align with a binary understanding of gender such as a person
who may identify as a combination of genders, who does not
define themselves as gendered, or who embodies a third
gender.
Nonbinary can include agender, bigender, demigender,
genderfluid, gender-nonconforming, gender-neutral,
genderqueer, pangender, or traditional third-genders such as
Two-Spirits and Muxes.

Gender Role

The culturally defined pattern of behavior, personality traits,
and attitudes that define masculinity and femininity.

Intersex

Used to describe a person who was born with variation in their
sex traits and reproductive anatomy such as gonads, internal
reproductive organs, external genitalia, and hormone
production.
Intersex is not used to describe individuals based on sex
chromosome configuration alone.

LGBTQ

An acronym for "Lesbian, Gay, Bisexual, Transgender, Queer
or Questioning, Intersex, and Allies."

"Top Surgery"

Surgical transition through breast augmentation mammoplasty
or subcutaneous mastectomy with chest contouring.

"Bottom Surgery"

Surgical transition through reproductive and/or genital organ
reconstruction or removal.

Risk-Reducing
Mastectomy

A prophylactic surgery that involves the removal of breast
tissue. A total mastectomy, complete removal of both breasts
including nipples, provides greater risk reduction than a
subcutaneous, nipple-sparing, mastectomy.

Sex/Sex Assigned at
Birth

Refers to physical and biological traits prior-to or following
birth such as sex chromosomes, gonads, internal reproductive
organs, and external genitalia. Typically described as male
(AMAB), female (AFAB), or intersex (AIAB or UAAB).

Transgender

Used to describe the full range of people whose gender
identity does not conform to the gender role that is culturally
associated with their sex assigned at birth.

Transitioning

The psychological, social, hormonal, surgical and legal
processes by which some people strive to more closely align
their gender identity and gender expression.

Two-Spirit

A pan-Indian term used to describe a Native American or
Alaskan Native who identifies with third gender or an
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alternative gender status. Many tribes and cultures have
additional specific terms for their nonbinary genders.

The National Cancer Institute (NCI) has been publicly documenting cancer incidence
data online in the Surveillance, Epidemiology, and End Results (SEER) Program since
1973. According to SEER, there were 1,806,590 new cases of cancer in 2020. While
most cancers are sporadic, approximately 5-10% of all cancer is hereditary, or caused by
a heritable genetic mutation in a cancer predisposition gene (Dalton et al., 2014). When
an individual has a genetic predisposition to cancer, they are at an increased risk for
developing certain types of cancer, depending on which gene has a mutation. Hereditary
cancers tend to occur at younger ages than sporadic cancers and individuals with a
hereditary cancer syndrome can have multiple cancers in their lifetime.
Based on these risks, the National Comprehensive Cancer Network (NCCN) has
published guidelines for genetic testing for hereditary cancer syndromes and cancer risk
management in individuals who have genetic cancer predispositions. These
recommendations for cancer screenings and preventative therapies aim to reduce the
probability that cancer will occur or reoccur in these individuals. If someone is at an
increased risk for developing cancer, recommendations may include earlier and increased
cancer surveillance or prophylactic surgical prevention.
Genetic counselors are healthcare professionals with training in both medical genetics
and psychosocial counseling. A cancer genetic counselor specializes in evaluating
patients for hereditary cancer syndromes. In a typical cancer genetic counseling session,
the genetic counselor elicits a patient’s personal and family medical history and conducts
a risk assessment to determine the likelihood that a patient’s cancer or the cancer in their
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family may be caused by a genetic predisposition syndrome. The genetic counselor then
communicates that risk assessment to the patient, facilitates decision making regarding
options for genetic testing, educates the patient on cancer surveillance and prevention,
and arranges genetic testing when appropriate (Schneider, 2011). During a genetic
counseling session, the counselor also explores psychosocial issues regarding motivations
for testing, feelings about the risk information, and overall emotional state of the patient.
When eliciting a patient’s family history, the genetic counselor will document the
information as a pedigree, or a diagram of the family tree. The National Society of
Genetic Counselors (NSGC) has established Practice Guidelines for Human Pedigree
Nomenclature, most recently revised in 2008. The NCCN has also published
recommendations for pedigree nomenclature that differ slightly from the NSGC Practice
Guidelines. The purpose of these guidelines is to create a universally accepted way to
accurately and appropriately represent individuals, their relationships, and their medical
status for risk assessment and future reference for other medical providers (Bennett et al.,
2008). Traditionally, based on the binarization of gender in most Western cultures,
females and males have been represented by circles and squares, respectively. If an
individual’s gender is unknown, they may be represented by a diamond according to the
NSGC guidelines or a combination of a square and circle per the NCCN (Bennett et al.,
2008; Sutherland et al., 2020). The lack of consensus creates confusion between medical
professionals and does not validate the gender identity of transgender patients. There
have been suggestions to create a unique symbol for transgender and nonbinary patients
within the field of genetic counseling, which underlines the need for standardization and
reform of the current practice guidelines (Sheehan et al., 2020; Tuite et al., 2020).
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The World Professional Association for Transgender Health (WPATH) published
Standards of Care for the Health of Transsexual, Transgender, and GenderNonconforming People. These Standards of Care guidelines describe therapies available
to aid in the transition from sex assigned at birth to true gender, including hormonal and
surgical options. There are some possible risks to taking these hormones, including a
potential increase in cancer risk, although much of the data is minimal and sometimes
conflicting (Sutherland et al., 2020).
Breast and chest reconstruction may be referred to as “top surgery” and typically
involves either a breast augmentation mammoplasty or a subcutaneous mastectomy with
chest contouring (Coleman et al., 2012). Subcutaneous, or nipple-sparing mastectomies,
are not typically prophylactic bilateral total mastectomies, which is the recommended
surgical prevention for some high-risk hereditary breast cancer syndromes (Alaofi et al.,
2018; Griepsma et al., 2014; Guillem et al., 2020). Additional surgical transitions may
include “bottom surgery,” or surgery involving reproductive and/or genital organ
reconstruction or removal (Coleman et al., 2012). Surgery to remove reproductive organs
such as the uterus (hysterectomy) or ovaries and fallopian tubes (salpingo-oophorectomy)
may be available for gender-affirming surgery. Currently, a risk-reducing salpingooophorectomy (RRSO) is the most effective means of decreasing ovarian cancer risk in
individuals with high-risk hereditary cancer syndromes (Guile et al., 2020). Surgery to
remove the prostate (prostatectomy) is not frequently offered as part of a genderaffirming surgery and is also not typically recommended in most cases of high-risk
hereditary cancer syndromes. Because there is limited data on the effects that these
therapies have on cancer risk, transgender and gender nonconforming patients who
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present for cancer risk assessment require a more personalized approach to discussing
gender-affirming interventions and management options (Sutherland et al., 2020).
There are significant barriers that limit access to gender-affirming therapies and
general healthcare services among gender-diverse populations (Berro, et al., 2019; Harb
et al., 2019; Haviland et al., 2020; Sacca et al., 2019; Sutherland et al., 2020; Zayhowski
et al., 2019). These barriers include lack of competent care, inhibited access to health
insurance, and limited availability of inclusive and comfortable healthcare environments
(Edmiston et al., 2016; Harb et al., 2019; Haviland et al., 2020). It has been shown that
healthcare providers with professional education and formal training regarding care for
lesbian, gay, bisexual, transgender, and questioning (LGBTQ) individuals demonstrate an
increase in knowledge and competency when serving these patient populations
(Hardacker et al., 2014; Johnson et al., 2016). Patients who are currently employed, have
higher annual incomes, have completed higher levels of education, and have health
insurance are more likely to adhere to cancer screening and prevention recommendations
than those who do not (Johnson et al., 2016). Adults who are of ethnic minorities are
more likely than white adults to identify as a gender minority, which can compound these
barriers and further limit and prevent access to medical care, ultimately leading to worse
health outcomes (Center for Disease Control and Prevention 2018).
Without the ability to document gender diversity in most medical record systems,
cancer rates among transgender people are poorly understood. The SEER database does
not collect gender identity information, therefore there is no way to determine cancer
rates among transgender patients at a population level. Individuals who are at high risk
for developing cancer, including individuals with hereditary cancer syndromes, have
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specific screening recommendations that they should follow based on what body tissues
they have. Breast tissue, one or both ovaries, a uterus, and/or a prostate are of specific
importance to transgender individuals, because these body systems are at an increased
risk for tumor development with many genetic predisposition syndromes. Based on the
information that is available, transgender individuals have been reported to have
extremely low uptake on all cancer screenings. Transgender and gender-nonconforming
individuals have lower proportions of routine colorectal cancer screening and are less
likely to adhere to breast cancer screening recommendations compared to cisgender
patients (Bazzi et al., 2015; Tabaac et al., 2018). Receiving less cancer surveillance
contributes to increased time to cancer diagnosis which leads to increased rates of
morbidity and mortality among transgender patients (Sutherland et al., 2020).
Little research has been conducted to assess the feelings and experiences of
transgender patients regarding current genetic counseling practices. In the NSGC 2020
Professional Status Survey–an internally administered survey that assesses metrics of
current genetic counselors such as demographics, salary, and workforce satisfaction–only
two genetic counselors indicated non-binary or third gender identities. The literature that
does exist regarding transgender patients is predominantly from the perspective of
genetic counselors, most of whom do not identify as transgender or non-binary, leaving
the transgender voice largely absent. Additionally, each of these studies calls for a greater
exploration of the views of transgender patients themselves. To our knowledge, no
research has been conducted to assess the perspectives of transgender individuals who
have not had cancer genetic counseling specifically regarding anticipated needs and
perceived barriers to accessing genetics care.

21

This population may be a significant portion of the patients seen in clinics, and there
are currently no standardized guidelines or recommendations for how to care for
transgender patients in a cancer genetics setting (Barnes et al., 2019; Rafferty 2018;
Sheehan et al., 2020). To meet the needs of this patient population, patient perspectives
must be assessed. This study aims to determine what aspects of current genetic
counseling practice and training need to be adapted in order to optimize cancer genetic
counseling strategies for this patient population. The primary goal of this study was to
determine the informational and psychosocial needs of adult transgender patients who
may present for cancer genetic counseling while identifying motivations and barriers to
seeking genetic counseling.
This study aimed to provide genetic counseling research surrounding transgender
healthcare, which is currently sparse and limited. While there is literature that assesses
the needs of patients who identify as a sexual minority, research regarding how genetic
counselors can meet the needs of transgender patients specifically is minimal
(VandenLangenberg et al., 2011). In the studies that include lesbian, gay, and bisexual
patients, genetic counselors report overall that they do not adjust their counseling
approaches (Glessner et al., 2012). Without intentional surveying of gender minority
patients, genetic counselors will remain underprepared to care for a portion of the patient
population. In existing literature, genetic counselors indicated a desire for more data and
education regarding counseling transgender patients (Zayhowski et al., 2019).
Identifying the needs of transgender patients adds to the cultural competence that
genetic counselors must have to effectively serve patients, making the information gained
from exploring these perspectives valuable to the profession. Cultural competency is a
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core value of the genetic counseling field, as it encourages genetic counselors to
understand each patient’s family, community, and culture to better empathize with
patients’ thoughts, feelings, and values. Understanding the motivations and needs of
transgender people who may present for cancer genetic counseling is the only way to
competently counsel these patients. It is the duty of genetic counselors to be
knowledgeable and sensitive to diverse languages, cultures, beliefs, and backgrounds to
provide optimal care (Warren & Wilson, 2013). The information gained from surveying
patients directly will prepare current and future genetic counselors for interactions with
all patients, including transgender and gender nonconforming patients.
We predicted that transgender individuals have needs within the cancer genetic
counseling session that are similar to cisgender patients, as well as needs that are unique
to their gender identity. We expected that transgender individuals would find value in
discussing how future healthcare plans regarding gender-affirming therapies could be
impacted by a hereditary predisposition to cancer. Results from this study may also
provide clarification on current practices regarding official pedigree standards.
2.3 Materials and Methods
2.3.1 Participants and Recruitment
Participants included English-speaking individuals over the age of 18 who identify as
transgender and/or nonbinary. Participants who were not over the age of 18 or did not
identify as transgender were excluded from the study. Only English-speaking participants
were included in this study due to limited resources for translation and interpretation
from English to other languages. Survey exclusion criteria is detailed in Figure 2.1.
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Figure 2.1 Methods by which participant eligibility was filtered to assess for eligibility.
Participants included in the grey boxes were excluded from the study and not assessed in
data analysis due to unmet inclusion criteria.

Participants were recruited via an advertisement (Appendix A) on multiple Facebook
pages for transgender individuals and hereditary cancer risk support groups. The
advertisement included a description of the study and a link to the online questionnaire.
Participation was voluntary and upon completion of the survey, respondents were given
the opportunity to enter a raffle for one of five $25 Visa gift cards. Participants also had
the opportunity to express interest in being contacted for a semi-structured phone
interview.
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2.3.2 Procedure
The questionnaire was administered online through Qualtrics.com and included Likert
scale, open-text entry, and multiple choice items. Data regarding gender identity,
demographics, motivations for attending a cancer genetic counseling session,
perspectives on current practices, personal medical history, and family history of cancer
was collected. Participants were able to skip any question or leave the questionnaire at
any time, so the completion rate varied. The semi-structured phone interviews were
conducted by the principal investigator (JB) and included similar themes as the
questionnaire.
Responses were collected from July to October 2020. Of the 105 individuals who
began the questionnaire, 87 participants submitted responses that were eligible for data
analysis. Eligible responses were reviewed and of the 87 respondents, 61 participants
provided answers to the entire questionnaire. Ten participants input their phone numbers
into the online software and were contacted for a phone interview. Verbal consent for
participation was requested at the beginning of each interview (Appendix C). On average,
the interviews lasted 25 minutes (range 15-40 minutes). Interviews were recorded on the
PI’s password protected computer and transcribed verbatim.
2.3.3 Data Analysis
Quantitative data were analyzed using descriptive statistics, reliability, and
correlations as appropriate. Quantitative data were analyzed using Microsoft Excel
software to perform Kruskal-Wallis (KW) test and Mann-Whitney U test for differences
and associations between groups. Figures and tables were constructed using Microsoft
PowerPoint software. The level of comfort and agreeability to several statements was
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assessed using a Likert scale (1=strongly disagree; 5=strongly agree) and were
represented with descriptive statistics (percentages, frequencies, and means). Due to lack
of responses in the open-text entry fields, the qualitative data were descriptively
summarized. Quotations from open-text entries and interviews were extracted and
organized into categories when available.
2.4 Results
2.4.1 Demographic Information
Of the 87 eligible respondents, 100% disclosed their gender identity with most
participants identifying with more than one gender (Table 2.2). Demographic information
such as age, race and ethnicity, education and employment, etc. was provided for 61
participants (Table 2.3). The majority of participants were between 18- and 38-years-old,
with most participants being 25- to 31-years-old. Almost all participants identified as
White and Non-Hispanic. Participant education level ranged from some high school
education to completed graduate degrees. Employed respondents with private health
insurance were more likely to receive care from a center that specializes in transgender
healthcare than participants who were unemployed or uninsured (Figure 2.2).

Table 2.2 Participant Gender Identity Information
Gender
Total (N)

Percent (%)

Agender

5

8%

Bigender

2

3%

Demigender

2

3%

Genderfluid

5

8%

Genderqueer

9

15%

Gender-nonconforming

8

13%

Gender-neutral

3

5%
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Gender-questioning

1

2%

Gender-transitioning

4

7%

Nonbinary

20

33%

Transgender man

27

44%

Transgender masculine

11

18%

Transgender feminine

9

15%

Transgender woman

17

28%

Two-spirit

2

3%

Prefer to self-describe

3

5%

Prefer not to say

0

0%

Table 2.3 Participant Demographic Information
Participant characteristic
Total (N)

Percent (%)

Age
18-24 years old

15

25%

25-31 years old

18

30%

32-38 years old

12

20%

39-45 years old

8

13%

46-52 years old

1

2%

53-59 years old

5

8%

60-66 years old

1

2%

67-73 years old

1

2%

74 years or older

0

0%

Prefer not to say

0

0%

African American or Black

0

0%

American Indian or
Alaskan Native

1

2%

Asian

2

3%

Caucasian or White

56

92%

Pacific Islander

0

0%

Prefer to self-describe

0

0%

Race

27

Prefer not to say

2

3%

Hispanic or Latinx

5

8%

Not Hispanic or Latinx

53

87%

Prefer not to say

3

5%

Ethnicity

Education level

0%

Some high school

3

5%

High school diploma or
equivalent

3

5%

Some college

22

36%

Technical, trade, or
vocational training

2

3%

College graduate

17

28%

Graduate degree

12

20%

Prefer not to say

2

3%

Student

10

16%

Homemaker

1

2%

Military

0

0%

Employed

39

64%

Unemployed

5

8%

Retired

1

2%

Unable to work

3

5%

Prefer not to say

2

3%

$29,999 or less

16

26%

$30,000-39,999

11

18%

$40,000-49,999

8

13%

$50,000-59,999

4

7%

$60,000-69,999

7

11%

$70,000 or more

13

21%

Prefer not to say

2

3%

Employment

Income

Insurance

28

No health insurance

9

15%

Private health insurance

40

66%

Public health insurance

10

16%

Prefer not to say

2

3%

Receiving healthcare from a center that specializes in transgender healthcare
Yes

37

61%

No

22

36%

Prefer not to say

2

3%

Figure 2.2 The impact of employment and health insurance status on receiving
specialized healthcare at a center for transgender patients.

2.4.2 Personal and Family History of Cancer
Four participants had a previous diagnosis of cancer including breast cancer at 45years-old, cervical cancer at 25-years-old, bladder cancer at 29-years-old, and laryngeal
cancer at 69-years-old. Although approximately half (42%) respondents reported limited
knowledge of their family health history, 63 participants indicated a family history of at
least one first- or second-degree relative who was diagnosed with cancer (Figure 2.3).
The total number of cancer diagnoses reported exceeds 228 cases. On average,
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participants had about 3 relatives who have been diagnosed with cancer. The most
frequently reported types of cancer, when known, for these relatives was breast cancer
and melanoma which were present in 43% and 41% of families, respectively.

Figure 2.3 Number of participants that indicated how many of their first- and seconddegree relatives have been diagnosed with cancer.

2.4.3 Current Practices
The questionnaire asked participants to rate their level of comfort with different
statements addressing the current practices of cancer genetic counselors using a Likert
scale (1=strongly disagree; 4=strongly agree). Participants were asked generally about the
importance of inclusivity within healthcare offices and appointments, preferred methods
of disclosing information, and specifically about comfort communicating with family
members (Table 2.4; Table 2.5).
Most participants (89%) indicated that it is important to have visible signs in the
waiting room or lobby regarding LGBTQ inclusivity. A large portion of participants
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agreed that it is important for medical professionals use appropriate and inclusive
language both on intake forms and during the appointment. Participants generally
indicated that they would feel comfortable sharing cancer risk information with their
relatives, both with and without assistance from a genetic counselor (Table 2.4; Figure
2.4). Most participants (79%) who indicated they would not share cancer risk information
with their families without the assistance of a genetic counselor said they would if they
did have that assistance in the form of a family letter, phone call, or family appointment.
Some participants indicated that the importance of each item would depend on the
specific situation or circumstances and elaborated in the open-text entry field associated
with that section of the survey.

Table 2.4 Comfort Levels Sharing Information Related to Cancer Risk
Strongly
Strongly
It depends
disagree
Disagree
Agree
agree
N (%)
Statement
N (%)
N (%)
N (%)
N (%)
If I was at an
increased risk to
develop cancer due
to a genetic cause, I
would feel
4 (6.4%)
comfortable sharing
this with my
relatives without
assistance from a
genetic counselor.

10 (15.9%) 21 (33.3%) 17 (27%)

If I was at an
increased risk to
develop cancer due
to a genetic cause, I
0 (0%)
would feel
comfortable sharing
this with my
relatives with
assistance from a

5 (8.1%)

10 (15.9%)

32 (51.6%) 16 (25.8%) 7 (11.3%)
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genetic counselor
like a family letter,
phone call, or
follow-up
appointment.

Table 2.5 Comfort Levels Disclosing Information Related to Gender
Strongly
disagree
Disagree
Agree

Strongly
agree

Statement

N (%)

N (%)

N (%)

I would prefer being asked
directly about my pronouns over
voluntarily sharing them.

3 (4.8%)

2 (3.2%)

25 (40.3%) 29 (46.8%)

I would feel comfortable sharing
my pronouns on an intake form
before my genetic counseling
appointment.

0 (0%)

1 (1.6%)

22 (36.1%) 38 (62.3%)

I would feel comfortable sharing
my pronouns with my genetic
counselor as soon as I am called
from the waiting room.

5 (8.2%)

9 (14.8%)

25 (41%)

I would feel comfortable sharing
my pronouns with my genetic
counselor when I am inside their
office.

1 (1.6%)

4 (6.6%)

30 (49.2%) 26 (42.6%)

I would feel comfortable sharing
my pronouns after the genetic
counselor shared theirs.

1 (1.6%)

3 (4.9%)

19 (31.2%) 37 (60.7%)

I would feel comfortable
disclosing any gender-affirming
hormones and surgeries I've had
on an intake form before my
genetic counseling appointment.

0 (0%)

11 (18%)

21 (34.4%) 28 (45.9%)

I would feel comfortable
disclosing any gender-affirming
hormones and surgeries I've had
during my genetic counseling
appointment.

0 (0%)

3 (4.9%)

26 (42.6%) 30 (49.2%)
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N (%)

22 (36.1%)

Figure 2.4 Participant responses to questions regarding the importance of inclusivity
before and during genetic counseling appointments and comfort with sharing cancer risk
information with relatives.

Although comfort levels between sharing pronouns, hormone history, and surgical
history was not significantly different between being asked on an intake form or in
person, respondents expressed the highest level of agreement to “I would feel
comfortable sharing my pronouns on an intake form before my genetic counseling
appointment” (p=0.65; Figure 2.5). Between available options for pedigree
nomenclature, respondents were significantly less comfortable with being represented as
their sex assigned at birth (H(2)=39.88, p=2.18E-09; Figure 2.6).
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Figure 2.5 Participant responses to questions regarding the most comfortable way to
disclose pronouns, hormone use, and surgical history.

Figure 2.6 Participant responses to questions regarding comfort levels with current
pedigree nomenclature.

2.4.4 Motivations
Roughly two-thirds of participants strongly agreed that they would value discussing
hormone therapies and gender-affirming surgeries in relation to personal cancer risk
during a genetic counseling session. Other motivations for which participants expressed a
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high level of agreeance with included to gain information about personal cancer risk
assistance as well as understanding options for cancer prevention, risk-reduction, and
detection (Table 2.6; Figure 2.7; Figure 2.8). Although a majority of participants
expressed agreement with the statements “I would value learning about the cancer risk
for my relatives,” and “I would value discussing how my cancer risk could impact my
family planning decisions,” these ranked the lowest among the agreed with statements
(Figure 2.7).

Table 2.6 Motivations for Seeking Cancer Genetic Counseling
Strongly
disagree
Disagree
Agree

Strongly
agree

Statement

N (%)

N (%)

N (%)

N (%)

I would value learning about my
personal cancer risk.

0 (0%)

0 (0%)

30 (50%)

30 (50%)

I would value learning about the
cancer risk for my children.

4 (6.9%)

9 (15.5%)

16 (27.6%) 16 (27.6%)

I would value learning about the
cancer risk for my relatives.

1 (1.7%)

7 (11.9%)

32 (54.2%) 19 (32.2%)

I would value having someone to
help me understand how my
personal and family history
impacts my cancer risk.

0 (0%)

1 (1.7%)

29 (49.2%) 29 (49.2%)

I would value discussing my
thoughts and feelings about my
cancer risk.

0 (0%)

3 (5.1%)

29 (49.2%) 26 (44.1%)

I would value discussing my
thoughts and feelings about my
genetic test results.

0 (0%)

1 (1.7%)

26 (44.1%) 31 (52.5%)

I would value discussing my
thoughts and feelings about
cancer screening procedures.

0 (0%)

2 (3.4%)

31 (52.5%) 26 (44.1%)

10 (17%)

20 (33.9%) 18 (30.5%)

I would value discussing how my
cancer risk could impact my
2 (3.4%)
family planning decisions.
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I would value discussing
hormone therapies and genderaffirming surgeries as they relate
to my cancer risk.

1 (1.7%)

0 (0%)

20 (34.5%) 37 (63.8%)

I would value having someone to
help me understand my options
for cancer detection.

0 (0%)

2 (3.4%)

27 (45.8%) 30 (50.9%)

I would value having someone to
help me understand my options
for cancer prevention and riskreduction.

0 (0%)

0 (0%)

23 (39%)

I would value having someone to
help me decide if genetic testing
is right for me.

0 (0%)

0 (0%)

27 (45.8%) 30 (50.9%)

I would value discussing costs
relating to genetic testing and
follow-up screening.

0 (0%)

1 (1.7%)

23 (39%)

I would value having someone to
help me understand the privacy
and confidentiality policies
surrounding genetic test results.

0 (0%)

3 (5.1%)

29 (49.2%) 26 (44.1%)

36 (61%)

35 (59.3%)

Figure 2.7 Participant responses to questions regarding motivations related to personal
and family cancer risk.
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Figure 2.8 Participant responses to questions regarding motivations related to genetic
testing and cancer detection, prevention, and risk-reduction.

Most respondents have taken or have considered taking gender-affirming hormones
(Table 2.7). A majority of participants have had or have considered having chest or breast
surgery. Almost half of participants who were born with ovaries have had or considered
having an oophorectomy and over half of respondents who were born with a uterus have
had or considered having a hysterectomy. Of the participants who were born with a
prostate, most have not had or considered having a prostatectomy.

Table 2.7 Participant Hormone and Surgical History Information
Yes
No
Prefer not to say
N (%)

N (%)

N (%)

Have you ever taken, or considered
taking, gender-affirming hormones?

53 (88%)

7 (12%)

0 (0%)

Have you ever had, or considered
having, surgery on your breast tissue
(lumpectomy, mastectomy, breast
augmentation, chest reconstruction)?

49 (82%)

8 (13%)

3 (5%)

If you were born with ovaries, have
you ever had, or considered having,

19 (48%)

10 (25%)

11 (28%)
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surgery to remove your ovaries
(oophorectomy)?
If you were born with a uterus, have
you ever had, or considered having,
surgery to remove your uterus
(hysterectomy)?

22 (54%)

10 (24%)

9 (22%)

If you were born with a prostate, have
you ever had, or considered having,
surgery to remove your prostate
(prostatectomy)?

4 (21%)

14 (74%)

1 (5%)

2.4.5 Qualitative Results
In each survey, participants had the opportunity to answer open-text response
questions and provide information or elaborate on the responses they provided. Of the ten
individuals who were contacted, six participants completed a follow-up telephone
interview. Direct quotes are extracted from open-text entries and telephone interview.
When given the opportunity to expand on their family history of cancer, some
individuals specified which relatives had cancer, provided information about “other”
types of cancer, and/or explained why they did not know about their family history of
cancer. The amount of detail provided by each participant varied greatly and did not
correlate with the amount of information the participant indicated they knew about their
family medical history. Listed below are quotes from participants regarding their family
history of cancer.
1. “Dad died of prostate cancer. Brother had a prostatectomy.”
2. “Great-grandmother had breast cancer.”
3. “Grandmother had colon cancer in her early 50s. At 73 she developed stomach,
liver, and other cancer that had metastasized from which she passed of within 2
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weeks of diagnosis. Prostate cancer from maternal grandfather’s brother.
Bladder cancer from maternal uncle.”
4. “Maternal grandmother and sister both died from ovarian and endometrial
cancer.”
5. “The ‘other’ cancers are basal cell carcinomas.”
6. “My aunt had breast cancer and received chemo and they removed her breast
tissue on that side. Another aunt had [ovarian] cancer.”
7. “2 aunts of mother’s side, my father, 1+ on my father’s side. Family is fractured,
data incomplete.”
8. “I don’t know because I’m adopted with no contact with [my biological] family. I
was diagnosed with a ductal hyperplasia”
Listed below are quotes from participants regarding comfort levels with current
genetic counseling pedigree nomenclature and suggestions for fostering inclusivity as a
healthcare professional.
9. “I understand in the medical field it can be important to look at birth gender
when assessing risks or looking at treatments, so it wouldn't bother me to have
that information be a part of the process. I would just prefer being referred to as
my chosen gender and pronouns when we're speaking and on any regular
paperwork.”
10. “I usually don’t mind sharing any hormone related medication on intake forms,
surgeries are usually left unstated unless such information is deemed necessary.”
11. “I would only be comfortable with the AFAB identifier after gender affirming
surgery.”
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12. “We live our lives mostly telling people who we are. It's much nicer to write it
down and pass it to said people of an office rather than someone saying out loud
in front of strangers. Also, being asked is so much nicer and more comfortable
than having to correct someone or tell them straight forward what you prefer.”
13. “Having a pronoun field on the intake sheet helps to standardize sharing
pronouns and is a great step to making the process more inclusive.”
14. “I've been very fortunate in my medical experiences so far, but I'm always a little
nervous when seeing a new doctor for the first time. Seeing some sort of LGBT+
support information in the lobby or on their website would be very comforting.”
15. “Medical facilities should always be safe places because you are poked and
tested so much anyways. It is important to still keep up with doctors to know the
health of your body and you should never feel scared to go to the doctors you
need [because you are transgender]. [Healthcare is] needed to sustain a long and
healthy life. So, it should be apparent from the moment you touch the front door
of an office with a sticker or sign saying, “we include everyone including
LGBTQ+”. Some of the worst moments of my life have been in a doctor’s office
and I don’t want that for others.”
Listed below are quotes from participants regarding potential motivations for seeking
cancer genetic counseling. Some participants expanded on what they would like to have
addressed during a session and other provided insight on why certain statements were
less motivating.
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16. “We always hear that there are risks from taking [hormones] but there is never a
long conversation about exactly what those risks are, especially about cancer,
nobody really asks about that.”
17. “Given our understanding of how transgender hormone therapies and surgeries
are still not well understood in the long term, I would find it very helpful to have
some of that information included in an overview of my potential cancer risks.”
18. “I have always planned to foster/adopt children and do not plan on having any
biological children.”
19. “It would be nice to have someone say, ‘this is your risk and here’s why,’ so if a
genetic counselor could do that, I would go.”
20. “I feel like I would just want to make sure I was doing the right cancer
screenings, so I don’t get blindsided by anything.”
2.5 Discussion
2.5.1 Discussion
This study explored perspectives of transgender individuals who may present for
hereditary cancer genetic counseling regarding the primary informational and
psychosocial needs, motivations for seeking cancer counseling, and barriers to accessing
or attending genetic counseling. The purpose of this study was to gain a better
understanding of what areas of current genetic counseling practice and formal education
need to be evolved to provide optimized, comprehensive, and inclusive care for this
patient population. While the perceptions of genetic counselors on trans-inclusive
counseling have been investigated previously (Barnes et al., 2019; Berro et al., 2019;
Sacca et al., 2019; Sheehan et al., 2020; Zayhowski, et al., 2019) each of these studies
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calls for a direct assessment of patient-reported educational and psychosocial needs of
transgender patients.
We predicted that transgender and nonbinary individuals would have needs within the
cancer genetic counseling session that are similar to cisgender patients, as well as needs
that are unique to their gender identity. We expected that participants would find value in
and be motivated by the opportunity to discuss how future healthcare plans regarding
hormone and surgical transitioning could be impacted by a hereditary predisposition to
cancer. We also aimed to obtain clarification on opinions on the current, official pedigree
nomenclature standards.
The information revealed in this study is similar to what has been previously reported
for transgender patients in genetic counseling in general, emphasizing the importance of
adapting to the self-reported needs of this patient population. Specific themes highlighted
are that transgender individuals have both similar and diverse motivations and needs
related to hereditary cancer genetic counseling, patient agreeance with the current and
proposed pedigree nomenclature varies between methodologies, and that there are
barriers to accessing care that genetic counselors should be aware of and take into
consideration while counseling transgender patients.
Common motivations among both transgender and cisgender individuals regarding
seeking hereditary cancer genetic counseling include learning about personal cancer risk,
attempting to better understand options for cancer prevention and risk-reduction, and
having someone to help that individual decide if, and when, genetic testing may be right
for them. Since every respondent either agreed or strongly agreed with those statements,
it can be inferred that these motivations are not impacted by gender identity and would be
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the same across both cisgender and transgender patient populations. All respondents
agreed with the statement about cancer prevention and risk-reduction was unexpected
because transgender patients typically have an extremely low uptake and adherence to
most cancer screening recommendations compared to cisgender patients of the same age
and health status (Bazzi et al., 2015; Tabaac et al. 2018). Patients who are currently
employed, have higher annual incomes, have completed higher levels of education, and
have health insurance are more likely to adhere to cancer screening and prevention
recommendations than those who do not (Johnson et al., 2016). A potential explanation
for the strong agreeance with learning about cancer prevention and risk-reduction could
be the unequal distribution of participants who are employed and have private health
insurance. We found that these participants are more likely to receive medical care from a
center that specializes in transgender healthcare, which could increase comfort and access
to cancer screenings that transgender patients may not otherwise seek.
Roughly half of participants said they would be motivated to learn about the cancer
risk for their children and other relatives. For most cisgender cancer genetic counseling
patients, genetic counselors discuss familial implications and how these family members
could be impacted by the patient pursuing genetic testing, in terms of both benefits and
limitations. Although many participants indicated agreeance with learning this
information, the concordance was not as high as that seen for other topics. This may
result in less time needing to be spent on this topic in a cancer genetic counseling session.
Unsurprisingly, all but one participant agreed or strongly agreed that discussing hormone
therapies and gender-affirming surgeries as they relate to personal cancer risk would be a
motivating factor for seeking genetic counseling, which is a need specific to this patient
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population. Most respondents reported that they have or have considered both surgical
and hormonal therapies as a part of their transition process. Participants cited the lack of
concrete information regarding cancer risks associated with hormone use as one reason
that they would like to discuss hormone use during a genetic counseling session. There
are some cisgender patients who may have had previous chest or breast surgery, an
oophorectomy, a hysterectomy, or taken hormones, however the frequency of these
surgical interventions and hormonal therapies in the cisgender population is significantly
less than in the transgender population. In addition, depending on age at time of
evaluation, transgender patients may have a longer history of hormone use.
Participants were asked to indicate their level of agreement with the comfortability,
and therefore appropriateness, of current guidelines and proposed changes to pedigree
nomenclature regarding gender. Most participants disagreed or strongly disagreed with
being represented as their sex assigned at birth on a pedigree, which is one interpretation
of the latest NSGC guidelines which indicate that it is appropriate to assign gender based
on phenotype. This information supports previous data that calls for revision and
standardization of pedigree nomenclature to increase comfort of patients while
maintaining accuracy (Barnes et al., 2019; Rafferty 2018; Sheehan et al., 2020).
Participants were most comfortable being represented as their gender identity with an
abbreviation of their sex assigned at birth under the symbol. Genetic counselors and
transgender individuals alike have proposed an additional symbol, a hexagon, that would
indicate a nonbinary individual rather than not specifying their gender (Sheehan et al.,
2020; von Vaupel-Klein, & Walsh, 2020). The data from this study supports that
proposal, as most participants would feel most comfortable being represented as their
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gender identity, and there are currently no symbols outside of the binary male and female,
or unknown gender. It is inappropriate to indicate that a transgender or nonbinary patient
is an unknown gender if they identify with either, or both, of those genders.
2.5.2 Practice Implications
Patients expressed that it would be more comfortable to share pronouns and hormonal
and surgical interventions on an intake form prior to the genetic counseling appointment,
as opposed to in person during the visit. Some individuals expressed that having an
inclusive intake form is a way to build trust between the healthcare provider and the
patient before they meet. Genetic counselors seeing patients for hereditary cancer
evaluations, as well as in other settings, should make a conscious effort to revise their
current intake procedures to include the option for “other” genders besides the binary
male and female in addition to asking about pronouns, which may go along with
“preferred name” or “title” sections that are already a part of many institution’s intake
paperwork. Increased comfort with providers builds trust between that provider and the
patient, which may ultimately lead to stronger adherence to recommendations, such as a
cancer screening.
Creation and implementation of a standardized pedigree nomenclature that includes
appropriate designations for transgender and nonbinary individuals is a crucial next step
for the profession. A revision of the current NSGC Standardized Pedigree Nomenclature
will allow this patient population to be represented accurately while setting the example
for other professional societies to make adjustments to their pedigree nomenclature that
supports inclusive patient care.
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Since most patients were motivated by the desire to discuss how their hormone and
surgical history impacts their cancer risk, it is important for genetic counselors to be
aware of which hormone therapies and surgical approaches are commonly available to
transgender patients and how these may be similar or different to hormone therapies and
surgeries that may be recommended or included in cancer management of cisgender
patients. For example, it would be important for cancer genetic counselors to know
gender-affirming masculinizing top surgeries do not reduce breast cancer risk
equivalently to a risk-reducing bilateral mastectomy, which is recommended in some
cases of hereditary cancer. It has been shown that healthcare providers with professional
education and formal training regarding care for lesbian, gay, bisexual, transgender, and
questioning individuals demonstrate an increase in knowledge and competency when
serving these patient populations (Hardacker et al. 2014; Johnson et al. 2016). Therefore,
genetic counselors would benefit from formal education either during their training
programs or as a part of continuing education.
2.5.3 Limitations and Future Research
The results of this study are limited by a small sample size (n=87), which inhibited
the ability to assess significance of data. Sample size may be partially explained by the
requirement that participants be fluent in English reading and writing. In addition, our
demographics were heavily skewed towards college-educated, Caucasian participants,
therefore these findings may not be generalized to ethnic minority transgender
individuals or transgender individuals who have not entered any post-secondary
education. The utility of investigation of the same themes in transgender people of racial
and ethnic minorities as well as diverse education levels lies in comparing the data from
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this study and similar studies to data gathered from a population where additional
intersectional health equities are present.
In order to be eligible for participation in this study, participants had to be 18 years of
age or older. Our study was primarily composed of respondents between the ages of 18and 38-years-old. Identified themes from this study may not be representative of other
cohorts. It may be beneficial in future research studies to explore the perspectives of
transgender individuals who are under the age of 18, as it is more likely that minors have
not yet begun hormonal or surgical therapies, which may have an effect on motivations
and needs in a cancer genetic counseling setting. This information could inform when
transgender patients should be asked about family history of cancer and henceforth
referred to genetic counseling when appropriate. Providing early cancer risk education
may impact transgender medical management in ways that are not well studied.

47

CHAPTER 3
CONCLUSIONS
Transgender individuals have both similar and diverse motivations and needs related
to hereditary cancer genetic counseling when compared to cisgender individuals.
Common motivations among both patient populations include learning about personal
cancer risk, attempting to better understand options for cancer prevention and riskreduction, and having someone facilitating the decision-making process surrounding
hereditary cancer genetic testing.
Implications regarding children and other relatives was not found to be strongly
motivating, although these are common motivations in cisgender patients. Transgender
patients have unique needs in terms of risk education regarding hormone use and surgical
interventions. Many transgender individuals will have or will consider both hormonal and
surgical interventions, which may or may not impact cancer risk. Genetic counselors
should be prepared to address this topic during sessions with transgender patients, which
would be best supported by formal education on transgender healthcare needs.
Transgender patients may be more comfortable disclosing information regarding
pronouns and hormonal and surgical history on an intake form, rather than in person with
the genetic counselor. It is important that genetic counselors take this into consideration
when creating and revising intake forms. Allowing patients to indicate a gender other
than male or female, or list their pronouns, is one way to be inclusive and foster a
comfortable setting for transgender patients. Another effort towards inclusivity would be
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the creation and implementation of a standardized pedigree nomenclature that includes
appropriate designations for transgender and nonbinary individuals, taking their
suggestions and preferences into consideration.
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APPENDIX A
PARTICIPANT RECRUITMENT SOCIAL MEDIA TEXT
The following text was posted to various social media platforms with a direct link to the
survey.

Jacqueline Baquet, a genetic counseling student at the University of South Carolina, is
working on a thesis project to assess the needs of transgender individuals in a cancer
genetic counseling setting. This is an online survey for individuals whose gender identity
does not align with their gender assigned at birth.
Please consider participating if any of the following applies to you:
•

Have or have had cancer yourself

•

Have relatives that have or have had cancer

•

Are interested in learning about your cancer risks

•

Are interested in learning about genetic testing for hereditary cancer

•

Are interested in contributing to research that will benefit this healthcare field

Please share this post with anyone who may be eligible to participate in this survey.
Upon completion of the survey, you will be offered the option to enter a raffle for one of
five $25 Visa gift cards as compensation for your time.
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APPENDIX B
QUESTIONNAIRE
The following list of questions was used as an outline for the questionnaire after inclusion
criteria was met.
Where appropriate, the interviewees were asked to expand upon their answers.
1. Please select the gender(s) that best describe you:
2. Have you ever been diagnosed with cancer?
i. What type of cancer(s) have you been diagnosed with?
ii. How old were you when you were diagnosed with cancer?
3. How much do you feel you know about your family medical history?
4. Please select the number of relatives that have been diagnosed with the following
cancers:
i. Breast cancer
ii. Ovarian cancer
iii. Gastric/stomach cancer
iv. Colon/rectal cancer
v. Pancreatic cancer
vi. Melanoma
vii. Prostate cancer
viii. Endometrial/uterine cancer
ix. Other cancer
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x. Unsure what type of cancer
4. Please select a response to the following considerations regarding a cancer genetic
counseling appointment:
i. If I was at an increased risk to develop cancer due to a genetic cause, I would
feel comfortable sharing this with my relatives without assistance from a genetic
counselor.
ii. If I was at an increased risk to develop cancer due to a genetic cause, I would
feel comfortable sharing this with my relatives with assistance from a genetic
counselor like a family letter, phone call, or follow-up appointment.
iii. It is important to me that medical intake forms ask about gender identity in an
inclusive way.
iv. It is important to me that medical professionals exchange pronouns with me.
v. It is important to me that medical professionals use inclusive language during
an appointment.
vi. It is important to me that I am represented in my medical records as my
gender, rather than my gender assigned at birth.
vii. It is important to me that medical offices display signs or other visual
representations of LGBTQ+ inclusivity in their waiting room.
5. Please select a response to the following considerations regarding a cancer genetic
counseling appointment:
i. I would prefer being asked directly about my pronouns over voluntarily sharing
them.
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ii. I would feel comfortable sharing my pronouns on an intake form before my
genetic counseling appointment.
iii. I would feel comfortable sharing my pronouns with my genetic counselor as
soon as I am called from the waiting room.
iv. I would feel comfortable sharing my pronouns with my genetic counselor
when I am inside their office.
v. I would feel comfortable sharing my pronouns after the genetic counselor
shared theirs.
vi. I would feel comfortable disclosing any gender-affirming hormones and
surgeries I've had on an intake form before my genetic counseling appointment.
vii. I would feel comfortable disclosing any gender-affirming hormones and
surgeries I've had during my genetic counseling appointment.
viii. I would feel comfortable being represented on the official pedigree as my
gender identity with AFAB/AMAB written underneath.
ix. I would feel comfortable being represented on the official pedigree as some
combination of my assigned sex and gender identity.
x. I would feel comfortable being represented on the official pedigree as my sex
assigned at birth.
6. Please select a response to the following considerations regarding a cancer genetic
counseling appointment:
i. I would value learning about my personal cancer risk.
ii. I would value learning about the cancer risk for my children.
iii. I would value learning about the cancer risk for my relatives.
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iv. I would value having someone to help me understand how my personal and
family history impacts my cancer risk.
v. I would value discussing my thoughts and feelings about my cancer risk.
vi. I would value discussing my thoughts and feelings about my genetic test
results.
vii. I would value discussing my thoughts and feelings about cancer screening
procedures.
viii. I would value discussing how my cancer risk could impact my family
planning decisions.
ix. I would value discussing hormone therapies and gender-affirming surgeries as
they relate to my cancer risk.
x. I would value having someone to help me understand my options for cancer
detection.
xi. I would value having someone to help me understand my options for cancer
prevention and risk-reduction.
xii. I would value having someone to help me decide if genetic testing is right for
me.
xiii. I would value discussing costs relating to genetic testing and follow-up
screening.
xiv. I would value having someone to help me understand the privacy and
confidentiality policies surrounding genetic test results.
7. Have you ever taken, or considered taking, gender-affirming hormones?
8. Have you ever had, or considered having, surgery on your breast tissue?
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9. Were you born with ovaries?
i. Have you ever had, or considered having, surgery to remove your ovaries?
10. Were you born with a uterus?
i. Have you ever had, or considered having, surgery to remove your uterus?
11. Were you born with a prostate?
i. Have you ever had, or considered having, surgery to remove your prostate?
12. What is your age?
13. Please select the race(s) that best describe you:
14. Please select the ethnicity that best describes you:
15. Please select the highest level of education you have completed:
16. Please select your employment status:
17. Please select the annual income that best describes your household:
18. Please select your current health insurance:
19. Do you currently receive care from a health center that specializes in health care for
transgender individuals?
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APPENDIX C
PHONE INTERVIEW
The following list of questions was used as an outline for the phone interview questions.
1. What are your pronouns?
2. How do you feel about discussing cancer risks with your family?
3. What about with your doctors?
4. Which of your doctors have asked you about your cancer family history?
i. What did they say?
ii. Is this something you wish would have been addressed?
5. Has any doctor ever talked to you about cancer as it relates to any hormones you have
taken or surgeries you have had?
i. What did they say?
ii. Is this something you wish would have been addressed?
6. Can you tell me about what you have been told regarding cancer screening?
7. How do you feel about cancer screenings?
i. Have you had any cancer screenings yourself? What type? Why not?
8. Do you think you might feel differently if you knew you were at an increased risk for
developing cancer?
9. What makes you most comfortable when visiting a new healthcare office?
10. What do you see as the largest benefit of pursuing cancer genetic counseling? What
would be your largest reservation about pursuing cancer genetic counseling?
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